

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims**

1.-14. (Canceled)

15. (Currently amended) A method for treating cancer in a subject, comprising administering to a subject having cancer (i) a composition of a taxoid molecule conjugated to a water soluble polymer and (ii) **external** radiation.

16. (Previously presented) The method of Claim 15, wherein said taxoid is paclitaxel and said water soluble polymer is polyglutamic acid.

17. (Previously presented) The method of Claim 15, wherein said taxoid is docetaxel and said water soluble polymer is polyglutamic acid.

18. (Previously presented) The method of Claim 16, wherein said polyglutamic acid has a molecular weight of about 5000 to about 100,000 daltons.

19. (Previously presented) The method of Claim 18, wherein said polyglutamic acid has a molecular weight of about 20,000 to about 80,000 daltons.

20. (Previously presented) The method of Claim 19, wherein said polyglutamic acid has a molecular weight of about 25,000 to about 50,000 daltons.

21. (Previously presented) The method of Claim 20, wherein said polyglutamic acid has a molecular weight of about 35,000 daltons.

22. (Previously presented) The method of Claim 20, wherein said composition comprises about 37% by weight paclitaxel.

23. (Previously presented) The method of Claim 20, wherein said composition comprises from about 2% to about 35% by weight of paclitaxel.

24. (Currently amended) The method of Claim 20, wherein said **external** radiation is gamma radiation.

25. (Currently amended) The method of Claim 22, wherein said composition is administered prior to said external radiation.

26. (Currently amended) The method of Claim 22, wherein said composition is administered following said external radiation.

27. (Previously presented) The method of Claim 22, wherein 14 GY radiation is administered.

28. (Previously presented) The method of Claim 22, wherein 7 GY radiation is administered.

29. (Currently amended) The method of Claim 22, wherein 10 GY radiation is administered administered.

30. (Previously presented) The method of Claim 29, wherein said 10 GY radiation is administered weekly.

31. (Currently amended) The method of Claim 30, wherein 50 to 70 GY [[Gray]] is administered over 5 to 7 weeks.

32. (Previously presented) The method of Claim 20, wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi's sarcoma.

33. (Previously presented) The method of Claim 25, wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi's sarcoma.

34. (Previously presented) The method of Claim 26, wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi's sarcoma.

35. (Previously presented) The method of Claim 15, wherein said polymer has a molecular weight of about 20000 to 80000 daltons.

36. (Previously presented) The method of Claim 15, wherein said polymer has a molecular weight of about 25000 to 50000 daltons.

37. (Currently amended) A method of enhancing the response of a tumor to external irradiation, comprising:

a) administering to a patient in need of such therapy a radiosensitizing amount of a pharmaceutical composition comprising paclitaxel, docetaxel, etoposide, teniposide, camptothecin or epothilone conjugated to a water soluble polyamino acid polymer and a pharmaceutically acceptable carrier;

b) irradiating said tumor with radiation from an external radiation source;

wherein said polymer has a molecular weight of about 5000 to 100000 daltons conjugated paclitaxel or docetaxel have increased water solubility, efficacy and accumulation within a tumor compared with the corresponding unconjugated drugs.

38. (Previously presented) The method of claim 37, wherein said polymer is polyglutamic acid having a molecular weight of about 20000 to about 80000 and said conjugate comprises about 2% to about 35% by weight of paclitaxel.

39. (Previously presented) The method of claim 37, wherein said polymer is polyglutamic acid having a molecular weight of about 20000 to about 80000 and said conjugate comprises about 2% to about 35% by weight of docetaxel.